Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more
Pacira BioSciences, Inc. (PCRX) - Total Liabilities
Latest total liabilities as of December 2025: $571.81 Million USD
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has total liabilities worth $571.81 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pacira BioSciences, Inc. - Total Liabilities Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pacira BioSciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Pacira BioSciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Information Services International-Dentsu Ltd
OTCGREY:IFMNF
|
USA | $55.59 Billion |
|
Smartgroup Corporation Ltd
PINK:STGXF
|
USA | $437.16 Million |
|
Xtep International Holdings Limited
F:4QI
|
Germany | €7.30 Billion |
|
Jizhong Energy Resources Co Ltd
SHE:000937
|
China | CN¥31.98 Billion |
|
Theon International Plc
AS:THEON
|
Netherlands | €183.77 Million |
|
ScanSource Inc
NASDAQ:SCSC
|
USA | $802.94 Million |
|
Fortune Real Estate Investment Trust
PINK:FRIVF
|
USA | $11.53 Billion |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
China | CN¥9.33 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Pacira BioSciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pacira BioSciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual total liabilities of Pacira BioSciences, Inc. from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $571.81 Million | -26.23% |
| 2024-12-31 | $775.17 Million | +10.07% |
| 2023-12-31 | $704.26 Million | -22.28% |
| 2022-12-31 | $906.19 Million | -32.62% |
| 2021-12-31 | $1.34 Billion | +105.39% |
| 2020-12-31 | $654.83 Million | +37.53% |
| 2019-12-31 | $476.12 Million | +29.34% |
| 2018-12-31 | $368.13 Million | +5.51% |
| 2017-12-31 | $348.89 Million | +102.27% |
| 2016-12-31 | $172.49 Million | +0.74% |
| 2015-12-31 | $171.23 Million | +10.52% |
| 2014-12-31 | $154.93 Million | +20.50% |
| 2013-12-31 | $128.57 Million | +178.30% |
| 2012-12-31 | $46.20 Million | -29.17% |
| 2011-12-31 | $65.22 Million | -43.26% |
| 2010-12-31 | $114.94 Million | +71.81% |
| 2009-12-31 | $66.90 Million | +55.40% |
| 2008-12-31 | $43.05 Million | -- |